Načítá se...
Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy
BACKGROUND: Transthyretin cardiomyopathy (TTR-CM) is a progressive, fatal disease caused by the accumulation of misfolded transthyretin (TTR) amyloid fibrils in the heart. Tafamidis is a kinetic stabilizer of TTR that inhibits misfolding and amyloid formation. METHODS: In this post hoc analysis, dat...
Uloženo v:
| Vydáno v: | Clin Med Insights Cardiol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5606341/ https://ncbi.nlm.nih.gov/pubmed/28951660 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1179546817730322 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|